Упрощенная HTML-версия
//Clinical MicrobiologyReviews.-20 0 1 .-Vol. 14,№3.-P . 528-
546.
50. Arankalle, V.A. Who should receive hepatitis A vaccine? / V.A.
Arankalle, M.S. Chadha // J. Viral. Hepat. - 2003. - № 10 (3). - P.
157-158.
51. Gamer, J.S. Hospital Infection Control PracticesAdvisoryCommittee.
Guideline for isolation precautions in hospitals /J.S. Gamer// Infect.
ControlHosp.Epidemiol.- 1996. -№ 17.-P . 53-80.
52. Immune response to a new hepatitis В vaccine in healthcare workers
who had not responded to standard vaccine: randomised double blind
dose-response study / J.N. Zuckerman, C. Sabin, F.M. Craig et al. //
BMJ. - 1997. - № 314. - P. 329.
53. Lok, Anna.S.F. Chronic Hepatitis B: AASLD Practice Guidelines /
Anna.S.F. Lok, Brian.J. McMahon [Электронный ресурс] / /Режим
доступа: http
54. Markers of disease activity in chronic hepatitis В virus infection / K.
Yalcin, H. Degertekin, F. Yildiz et al. // Clin. Invest. Med. - 2003. -
№ 26(1).-P . 27-34.
55. Poirriez, J. Some questions to be raised about the hepatitis В vaccine
/ J. Poirriez// Vaccine. - 2002. - № 20 (13). - P. 1696-1698.
56. Poole, C.J.M. Immunity to hepatitis В among health care workers
performing exposure prone procedures / C.J.M. Poole, S. Miller, G.
Fillingham/ / BMJ.- 1994.-№309.-P . 94-95.
57. Predicting the liver histology in chronic hepatitis C: how good is the
clinician? / J. Romagnuolo, G. Jhangri, L. Jewell et al. // Am. J.
Gastroenterol. - 2001. - № 96 (11). - P. 3165-3174.
58. Risk andmanagement ofblood-bome infection inHealthCareWorkers
/ E.M. Beltrami, I.T. Williams, C.N. Shapiro, M.E. Chamberland //
Clin. MicrobiologyReviews.-2000. -№ 13 (3).-P. 385-407.
59. Risk groups for hepatitisAvirus infection / E. Franco, С.Giambi, R.
lalacci et al. // Vaccine. - 2003 .-№21(19-20). - P. 2224-2233.
20